Skip to main content
Top
Published in: Digestive Diseases and Sciences 3/2020

01-03-2020 | Helicobacter Pylori | Review

Microbiome and Gastric Cancer

Authors: Lars Engstrand, David Y. Graham

Published in: Digestive Diseases and Sciences | Issue 3/2020

Login to get access

Abstract

The late 1800s Louis Pasteur and Robert Koch introduced and popularized the germ theory of disease. At that time, gastric cancer was the most common cause of cancer deaths in most countries making the stomach an early site of microbial research with a focus on gastric luminal and mucosal bacteria and the role of Boas-Oppler bacillus (Lactobacillus) in the diagnosis of gastric cancer. In the 1970s, the research focus evolved to studies of the gastric microbiome in the production of nitrosamines and included development of the Correa cascade. Interest in nitrosamine production peaked in the late 1980s and was replaced by studies of the newly described Helicobacter pylori and studies of its role in gastritis, gastric atrophy, and gastric cancer. The last decade has witnessed a rebirth in interest in the gastric microbiota as part of worldwide interest in the human microbiome. Although fungi were prominent in the studies of gastric microbiology in the nineteenth century, their potential role in disease pathogenesis has yet to be addressed using modern techniques. Overall, current studies of the gastric bacterial microbiome do not provide convincing evidence to expand the role of the gastric microbiome in cancer pathogenesis beyond what is directly attributable to the oncogenic potential of H. pylori and its role in persisting acute-on-chronic inflammation.
Literature
1.
go back to reference Tan MC, Balakrishnan M, Graham DY. Gastric cancer worldwide except Japan. In: Gastric cancer with special focus on studies from Japan. In: Shiotani A, ed. Gastric cancer with special focus on studies from Japan. Singapore: Springer; 2018:17–28. Tan MC, Balakrishnan M, Graham DY. Gastric cancer worldwide except Japan. In: Gastric cancer with special focus on studies from Japan. In: Shiotani A, ed. Gastric cancer with special focus on studies from Japan. Singapore: Springer; 2018:17–28.
2.
go back to reference von den Velden R. Ueber vorkommen und mandgel der freien salzsaure in magensaft bei gastrektasie. Deutsches Arch F Klin Med. 1879;23:369–399. von den Velden R. Ueber vorkommen und mandgel der freien salzsaure in magensaft bei gastrektasie. Deutsches Arch F Klin Med. 1879;23:369–399.
3.
go back to reference Graham DY, Asaka M. Eradication of gastric cancer and more efficient gastric cancer surveillance in Japan: two peas in a pod. J Gastroenterol. 2010;45:1–8.PubMed Graham DY, Asaka M. Eradication of gastric cancer and more efficient gastric cancer surveillance in Japan: two peas in a pod. J Gastroenterol. 2010;45:1–8.PubMed
4.
go back to reference Boas II, Oppler B. Zur kenntniss des mageninhalts beim carcinoma ventriculi. Deutsch Med Wchnsch. 1895;21:73–75. Boas II, Oppler B. Zur kenntniss des mageninhalts beim carcinoma ventriculi. Deutsch Med Wchnsch. 1895;21:73–75.
5.
go back to reference Boas I. Cancer of the Stomach. In: Boas I, Bernheim A, eds. Diseases of the stomach. Philadelphia: F.A. Davis Company; 1907:561–604. Boas I. Cancer of the Stomach. In: Boas I, Bernheim A, eds. Diseases of the stomach. Philadelphia: F.A. Davis Company; 1907:561–604.
6.
go back to reference Turck FB. The early diagnosis of carcinoma of the stomach, with bacteriology of the stomach contents. JAMA. 1895;24:317–319. Turck FB. The early diagnosis of carcinoma of the stomach, with bacteriology of the stomach contents. JAMA. 1895;24:317–319.
7.
go back to reference Turck FB. Combined gastroscope and gyromele for diagnostic and therapeutic purposes. JAMA. 1903;23:1412–1413. Turck FB. Combined gastroscope and gyromele for diagnostic and therapeutic purposes. JAMA. 1903;23:1412–1413.
8.
go back to reference Abelous JE. Recherches sur les microbes de l’estomac a L’etat normal et leur action sur les substances alimentares. In: Masson G, ed. Comptes rendus hebdomadaires des séances et mémoires de la Société de biologie. Paris: Library of the Academy of Medicine; 1889:86–89. Abelous JE. Recherches sur les microbes de l’estomac a L’etat normal et leur action sur les substances alimentares. In: Masson G, ed. Comptes rendus hebdomadaires des séances et mémoires de la Société de biologie. Paris: Library of the Academy of Medicine; 1889:86–89.
9.
go back to reference Schmidt R. Demonstration bakteriologischer Fazespraparte. Munch Med Wochenschr. 1903;50:2165. Schmidt R. Demonstration bakteriologischer Fazespraparte. Munch Med Wochenschr. 1903;50:2165.
11.
go back to reference Anonymous. The Boas-Oppler Bacillus. JAMA 1917;69(5):377. Anonymous. The Boas-Oppler Bacillus. JAMA 1917;69(5):377.
12.
go back to reference Comfort MW. Gastric acidity before and after development of gastric cancer: its etiologic, diagnostic and prognostic significance. Ann Intern Med. 1951;36:1331–1348. Comfort MW. Gastric acidity before and after development of gastric cancer: its etiologic, diagnostic and prognostic significance. Ann Intern Med. 1951;36:1331–1348.
13.
go back to reference Barber M, Franklin RH. Bacteriology of stomach and duodenum in cases of peptic ulcer and gastric carcinoma. Br Med J. 1946;1:951–953.PubMedPubMedCentral Barber M, Franklin RH. Bacteriology of stomach and duodenum in cases of peptic ulcer and gastric carcinoma. Br Med J. 1946;1:951–953.PubMedPubMedCentral
14.
go back to reference Spallanzani L. Experiences sur la digestion de L’homme et de diferentes especes d’animaux. Geneva: Chez Barthelemi Chirol, 1783. Spallanzani L. Experiences sur la digestion de L’homme et de diferentes especes d’animaux. Geneva: Chez Barthelemi Chirol, 1783.
16.
go back to reference Gillespie AL. The bacteria of the stomach. In: Woodhead German S, ed. The journal of pathology and bacteriology. Edinburgh: Young J. Pentland; 1893:279–302. Gillespie AL. The bacteria of the stomach. In: Woodhead German S, ed. The journal of pathology and bacteriology. Edinburgh: Young J. Pentland; 1893:279–302.
17.
go back to reference Giannella RA, Broitman SA, Zamcheck N. Gastric acid barrier to ingested microorganisms in man: studies in vivo and in vitro. Gut. 1972;13:251–256.PubMedPubMedCentral Giannella RA, Broitman SA, Zamcheck N. Gastric acid barrier to ingested microorganisms in man: studies in vivo and in vitro. Gut. 1972;13:251–256.PubMedPubMedCentral
18.
go back to reference Bartsch, H. O’Neill. I. K. and Shulte-Hermann.R. The Relevance of N-nitroso compounds to human cancer: Exposures and mechanisms. 1-658. 1987. Baden, Austria, IARC Scientific Publication No. 84. Proceedings of the IXth International Symposium on N-Nitroso Compounds. Bartsch, H. O’Neill. I. K. and Shulte-Hermann.R. The Relevance of N-nitroso compounds to human cancer: Exposures and mechanisms. 1-658. 1987. Baden, Austria, IARC Scientific Publication No. 84. Proceedings of the IXth International Symposium on N-Nitroso Compounds.
19.
go back to reference Jakszyn P, Bingham S, Pera G, et al. Endogenous versus exogenous exposure to N-nitroso compounds and gastric cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST) study. Carcinogenesis. 2006;27:1497–1501.PubMed Jakszyn P, Bingham S, Pera G, et al. Endogenous versus exogenous exposure to N-nitroso compounds and gastric cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST) study. Carcinogenesis. 2006;27:1497–1501.PubMed
20.
go back to reference Tricker AR, Preussmann R. Carcinogenic N-nitrosamines in the diet: occurrence, formation, mechanisms and carcinogenic potential. Mutat Res. 1991;259:277–289.PubMed Tricker AR, Preussmann R. Carcinogenic N-nitrosamines in the diet: occurrence, formation, mechanisms and carcinogenic potential. Mutat Res. 1991;259:277–289.PubMed
21.
go back to reference Xu L, Qu YH, Chu XD, et al. Urinary levels of N-nitroso compounds in relation to risk of gastric cancer: findings from the Shanghai cohort study. PLoS One. 2015;10:e0117326.PubMedPubMedCentral Xu L, Qu YH, Chu XD, et al. Urinary levels of N-nitroso compounds in relation to risk of gastric cancer: findings from the Shanghai cohort study. PLoS One. 2015;10:e0117326.PubMedPubMedCentral
22.
go back to reference Loh YH, Jakszyn P, Luben RN, et al. N-nitroso compounds and cancer incidence: the European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk Study. Am J Clin Nutr. 2011;93:1053–1061.PubMed Loh YH, Jakszyn P, Luben RN, et al. N-nitroso compounds and cancer incidence: the European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk Study. Am J Clin Nutr. 2011;93:1053–1061.PubMed
23.
go back to reference Gilchrist M, Winyard PG, Benjamin N. Dietary nitrate–good or bad? Nitric Oxide. 2010;22:104–109.PubMed Gilchrist M, Winyard PG, Benjamin N. Dietary nitrate–good or bad? Nitric Oxide. 2010;22:104–109.PubMed
24.
go back to reference Ward MH, Heineman EF, Markin RS, et al. Adenocarcinoma of the stomach and esophagus and drinking water and dietary sources of nitrate and nitrite. Int J Occup Environ Health. 2008;14:193–197.PubMed Ward MH, Heineman EF, Markin RS, et al. Adenocarcinoma of the stomach and esophagus and drinking water and dietary sources of nitrate and nitrite. Int J Occup Environ Health. 2008;14:193–197.PubMed
25.
go back to reference Keszei AP, Goldbohm RA, Schouten LJ, et al. Dietary N-nitroso compounds, endogenous nitrosation, and the risk of esophageal and gastric cancer subtypes in the Netherlands Cohort Study. Am J Clin Nutr. 2013;97:135–146.PubMed Keszei AP, Goldbohm RA, Schouten LJ, et al. Dietary N-nitroso compounds, endogenous nitrosation, and the risk of esophageal and gastric cancer subtypes in the Netherlands Cohort Study. Am J Clin Nutr. 2013;97:135–146.PubMed
26.
go back to reference Kobayashi J. Effect of diet and gut environment on the gastrointestinal formation of N-nitroso compounds: a review. Nitric Oxide. 2018;73:66–73.PubMed Kobayashi J. Effect of diet and gut environment on the gastrointestinal formation of N-nitroso compounds: a review. Nitric Oxide. 2018;73:66–73.PubMed
27.
go back to reference Correa P, Haenszel W, Cuello C, et al. A model for gastric cancer epidemiology. Lancet. 1975;2:58–60.PubMed Correa P, Haenszel W, Cuello C, et al. A model for gastric cancer epidemiology. Lancet. 1975;2:58–60.PubMed
28.
go back to reference Correa P, Cuello C, Gordillo G, et al. The gastric microenvironment in populations at high risk to stomach cancer. Natl Cancer Inst Monogr. 1979;79:167–170. Correa P, Cuello C, Gordillo G, et al. The gastric microenvironment in populations at high risk to stomach cancer. Natl Cancer Inst Monogr. 1979;79:167–170.
29.
go back to reference Montes G, Cuello C, Gordillo G, et al. Mutagenic activity of gastric juice. Cancer Lett. 1979;7:307–312.PubMed Montes G, Cuello C, Gordillo G, et al. Mutagenic activity of gastric juice. Cancer Lett. 1979;7:307–312.PubMed
30.
go back to reference Ruddell WS, Bone ES, Hill MJ, et al. Gastric-juice nitrite: a risk factor for cancer in the hypochlorhydric stomach? Lancet. 1976;2:1037–1039.PubMed Ruddell WS, Bone ES, Hill MJ, et al. Gastric-juice nitrite: a risk factor for cancer in the hypochlorhydric stomach? Lancet. 1976;2:1037–1039.PubMed
31.
go back to reference Ruddell WS, Blends LM, Walters CL. Proceedings: Nitrite and thiocyanate in gastric juice. Gut. 1976;17:401.PubMed Ruddell WS, Blends LM, Walters CL. Proceedings: Nitrite and thiocyanate in gastric juice. Gut. 1976;17:401.PubMed
32.
go back to reference Jakszyn P, Gonzalez CA. Nitrosamine and related food intake and gastric and oesophageal cancer risk: a systematic review of the epidemiological evidence. World J Gastroenterol. 2006;12:4296–4303.PubMedPubMedCentral Jakszyn P, Gonzalez CA. Nitrosamine and related food intake and gastric and oesophageal cancer risk: a systematic review of the epidemiological evidence. World J Gastroenterol. 2006;12:4296–4303.PubMedPubMedCentral
33.
go back to reference Choi NW, Miller AB, Fodor JG, et al. Consumption of precursors of N-nitroso compounds and human gastric cancer. IARC Sci Publ. 1987;84:492–496. Choi NW, Miller AB, Fodor JG, et al. Consumption of precursors of N-nitroso compounds and human gastric cancer. IARC Sci Publ. 1987;84:492–496.
34.
go back to reference Hall CN, Darkin D, Brimblecombe R, et al. Evaluation of the nitrosamine hypothesis of gastric carcinogenesis in precancerous conditions. Gut. 1986;27:491–498.PubMedPubMedCentral Hall CN, Darkin D, Brimblecombe R, et al. Evaluation of the nitrosamine hypothesis of gastric carcinogenesis in precancerous conditions. Gut. 1986;27:491–498.PubMedPubMedCentral
36.
go back to reference Sobala GM, Schorah CJ, Sanderson M, et al. Ascorbic acid in the human stomach. Gastroenterology. 1989;97:357–363.PubMed Sobala GM, Schorah CJ, Sanderson M, et al. Ascorbic acid in the human stomach. Gastroenterology. 1989;97:357–363.PubMed
37.
go back to reference Sobala GM, Pignatelli B, Schorah CJ, et al. Levels of nitrite, nitrate, N-nitroso compounds, ascorbic acid and total bile acids in gastric juice of patients with and without precancerous conditions of the stomach. Carcinogenesis. 1991;12:193–198.PubMed Sobala GM, Pignatelli B, Schorah CJ, et al. Levels of nitrite, nitrate, N-nitroso compounds, ascorbic acid and total bile acids in gastric juice of patients with and without precancerous conditions of the stomach. Carcinogenesis. 1991;12:193–198.PubMed
38.
go back to reference Petersen CP, Mills JC, Goldenring JR. Murine models of gastric corpus preneoplasia. Cell Mol Gastroenterol Hepatol. 2017;3:11–26.PubMed Petersen CP, Mills JC, Goldenring JR. Murine models of gastric corpus preneoplasia. Cell Mol Gastroenterol Hepatol. 2017;3:11–26.PubMed
39.
go back to reference Graham DY, Zou WY. Guilt by association: intestinal metaplasia does not progress to gastric cancer. Curr Opin Gastroenterol. 2018;34:458–464.PubMedPubMedCentral Graham DY, Zou WY. Guilt by association: intestinal metaplasia does not progress to gastric cancer. Curr Opin Gastroenterol. 2018;34:458–464.PubMedPubMedCentral
40.
go back to reference Nozaki K, Shimizu N, Ikehara Y, et al. Effect of early eradication on Helicobacter pylori-related gastric carcinogenesis in Mongolian gerbils. Cancer Sci. 2003;94:235–239.PubMed Nozaki K, Shimizu N, Ikehara Y, et al. Effect of early eradication on Helicobacter pylori-related gastric carcinogenesis in Mongolian gerbils. Cancer Sci. 2003;94:235–239.PubMed
41.
go back to reference Shimizu N, Ikehara Y, Inada K, et al. Eradication diminishes enhancing effects of Helicobacter pylori infection on glandular stomach carcinogenesis in Mongolian gerbils. Cancer Res. 2000;60:1512–1514.PubMed Shimizu N, Ikehara Y, Inada K, et al. Eradication diminishes enhancing effects of Helicobacter pylori infection on glandular stomach carcinogenesis in Mongolian gerbils. Cancer Res. 2000;60:1512–1514.PubMed
42.
go back to reference Shimizu N, Inada K, Nakanishi H, et al. Helicobacter pylori infection enhances glandular stomach carcinogenesis in Mongolian gerbils treated with chemical carcinogens. Carcinogenesis. 1999;20:669–676.PubMed Shimizu N, Inada K, Nakanishi H, et al. Helicobacter pylori infection enhances glandular stomach carcinogenesis in Mongolian gerbils treated with chemical carcinogens. Carcinogenesis. 1999;20:669–676.PubMed
43.
go back to reference Hayakawa Y, Fox JG, Gonda T, et al. Mouse models of gastric cancer. Cancers (Basel). 2013;5:92–130.PubMedCentral Hayakawa Y, Fox JG, Gonda T, et al. Mouse models of gastric cancer. Cancers (Basel). 2013;5:92–130.PubMedCentral
44.
go back to reference Tsuda A, Suda W, Morita H, et al. Influence of proton-pump inhibitors on the luminal microbiota in the gastrointestinal tract. Clin Transl Gastroenterol. 2015;6:e89.PubMedPubMedCentral Tsuda A, Suda W, Morita H, et al. Influence of proton-pump inhibitors on the luminal microbiota in the gastrointestinal tract. Clin Transl Gastroenterol. 2015;6:e89.PubMedPubMedCentral
45.
go back to reference Graham DY. Helicobacter pylori update: Gastric cancer, reliable therapy, and possible benefits. Gastroenterology. 2015;148:719–731.PubMed Graham DY. Helicobacter pylori update: Gastric cancer, reliable therapy, and possible benefits. Gastroenterology. 2015;148:719–731.PubMed
46.
go back to reference Miftahussurur M, Yamaoka Y, Graham DY. Helicobacter pylori as an oncogenic pathogen, revisited. Expert Rev Mol Med. 2017;19:e4.PubMedPubMedCentral Miftahussurur M, Yamaoka Y, Graham DY. Helicobacter pylori as an oncogenic pathogen, revisited. Expert Rev Mol Med. 2017;19:e4.PubMedPubMedCentral
47.
go back to reference Kamada T, Haruma K, Ito M, et al. Time trends in Helicobacter pylori infection and atrophic gastritis over 40 years in Japan. Helicobacter. 2015;20:192–198.PubMedPubMedCentral Kamada T, Haruma K, Ito M, et al. Time trends in Helicobacter pylori infection and atrophic gastritis over 40 years in Japan. Helicobacter. 2015;20:192–198.PubMedPubMedCentral
49.
go back to reference Hanada K, Graham DY. Helicobacter pylori and the molecular pathogenesis of intestinal-type gastric carcinoma. Expert Rev Anticancer Ther. 2014;14:947–954.PubMed Hanada K, Graham DY. Helicobacter pylori and the molecular pathogenesis of intestinal-type gastric carcinoma. Expert Rev Anticancer Ther. 2014;14:947–954.PubMed
50.
go back to reference Kidane D. Molecular mechanisms of H pylori-induced DNA double-strand breaks. Int J Mol Sci. 2018;19:2891.PubMedCentral Kidane D. Molecular mechanisms of H pylori-induced DNA double-strand breaks. Int J Mol Sci. 2018;19:2891.PubMedCentral
51.
go back to reference Choi IJ, Kook MC, Kim YI, et al. Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N Engl J Med. 2018;378:1085–1095.PubMed Choi IJ, Kook MC, Kim YI, et al. Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N Engl J Med. 2018;378:1085–1095.PubMed
52.
go back to reference Coati I, Fassan M, Farinati F, et al. Autoimmune gastritis: pathologist’s viewpoint. World J Gastroenterol. 2015;21:12179–12189.PubMedPubMedCentral Coati I, Fassan M, Farinati F, et al. Autoimmune gastritis: pathologist’s viewpoint. World J Gastroenterol. 2015;21:12179–12189.PubMedPubMedCentral
53.
go back to reference Marne C, Pallares R, Casanova A, et al. Gastric juice microflora in patients with gastric ulcer and gastric cancer. Eur J Clin Microbiol. 1985;4:426–427.PubMed Marne C, Pallares R, Casanova A, et al. Gastric juice microflora in patients with gastric ulcer and gastric cancer. Eur J Clin Microbiol. 1985;4:426–427.PubMed
54.
go back to reference Gray JD, Shiner M. Influence of gastric pH on gastric and jejunal flora. Gut. 1967;8:574–581.PubMed Gray JD, Shiner M. Influence of gastric pH on gastric and jejunal flora. Gut. 1967;8:574–581.PubMed
55.
go back to reference Sjostedt S, Kager L, Heimdahl A, et al. Microbial colonization of tumors in relation to the upper gastrointestinal tract in patients with gastric carcinoma. Ann Surg. 1988;207:341–346.PubMedPubMedCentral Sjostedt S, Kager L, Heimdahl A, et al. Microbial colonization of tumors in relation to the upper gastrointestinal tract in patients with gastric carcinoma. Ann Surg. 1988;207:341–346.PubMedPubMedCentral
56.
go back to reference Sjostedt S, Heimdahl A, Kager L, et al. Microbial colonization of the oropharynx, esophagus and stomach in patients with gastric diseases. Eur J Clin Microbiol. 1985;4:49–51.PubMed Sjostedt S, Heimdahl A, Kager L, et al. Microbial colonization of the oropharynx, esophagus and stomach in patients with gastric diseases. Eur J Clin Microbiol. 1985;4:49–51.PubMed
57.
go back to reference Minalyan A, Gabrielyan L, Scott D, et al. The gastric and intestinal microbiome: role of proton pump inhibitors. Curr Gastroenterol Rep. 2017;19:42.PubMedPubMedCentral Minalyan A, Gabrielyan L, Scott D, et al. The gastric and intestinal microbiome: role of proton pump inhibitors. Curr Gastroenterol Rep. 2017;19:42.PubMedPubMedCentral
58.
go back to reference Li TH, Qin Y, Sham PC, et al. Alterations in gastric microbiota after H. pylori eradication and in different histological stages of gastric carcinogenesis. Sci Rep. 2017;7:44935.PubMedPubMedCentral Li TH, Qin Y, Sham PC, et al. Alterations in gastric microbiota after H. pylori eradication and in different histological stages of gastric carcinogenesis. Sci Rep. 2017;7:44935.PubMedPubMedCentral
59.
go back to reference Massarrat S, Saniee P, Siavoshi F, et al. The Effect of Helicobacter pylori infection, aging, and consumption of proton pump inhibitor on fungal colonization in the stomach of dyspeptic patients. Front Microbiol. 2016;7:801.PubMedPubMedCentral Massarrat S, Saniee P, Siavoshi F, et al. The Effect of Helicobacter pylori infection, aging, and consumption of proton pump inhibitor on fungal colonization in the stomach of dyspeptic patients. Front Microbiol. 2016;7:801.PubMedPubMedCentral
60.
go back to reference Azab M, Doo L, Doo DH, et al. Comparison of the hospital-acquired Clostridium difficile infection risk of using proton pump inhibitors versus histamine-2 receptor antagonists for prophylaxis and treatment of stress ulcers: A systematic review and meta-analysis. Gut Liver. 2017;11:781–788.PubMedPubMedCentral Azab M, Doo L, Doo DH, et al. Comparison of the hospital-acquired Clostridium difficile infection risk of using proton pump inhibitors versus histamine-2 receptor antagonists for prophylaxis and treatment of stress ulcers: A systematic review and meta-analysis. Gut Liver. 2017;11:781–788.PubMedPubMedCentral
61.
go back to reference Rosen R, Hu L, Amirault J, et al. 16S community profiling identifies proton pump inhibitor related differences in gastric, lung, and oropharyngeal microflora. J Pediatr. 2015;166:917–923.PubMedPubMedCentral Rosen R, Hu L, Amirault J, et al. 16S community profiling identifies proton pump inhibitor related differences in gastric, lung, and oropharyngeal microflora. J Pediatr. 2015;166:917–923.PubMedPubMedCentral
62.
go back to reference Wang K, Lin HJ, Perng CL, et al. The effect of H2-receptor antagonist and proton pump inhibitor on microbial proliferation in the stomach. Hepatogastroenterology. 2004;51:1540–1543.PubMed Wang K, Lin HJ, Perng CL, et al. The effect of H2-receptor antagonist and proton pump inhibitor on microbial proliferation in the stomach. Hepatogastroenterology. 2004;51:1540–1543.PubMed
63.
go back to reference Peterson WL, Mackowiak PA, Barnett CC, et al. The human gastric bactericidal barrier: mechanisms of action, relative antibacterial activity, and dietary influences. J Infect Dis. 1989;159:979–983.PubMed Peterson WL, Mackowiak PA, Barnett CC, et al. The human gastric bactericidal barrier: mechanisms of action, relative antibacterial activity, and dietary influences. J Infect Dis. 1989;159:979–983.PubMed
65.
go back to reference Monstein HJ, Tiveljung A, Kraft CH, et al. Profiling of bacterial flora in gastric biopsies from patients with Helicobacter pylori-associated gastritis and histologically normal control individuals by temperature gradient gel electrophoresis and 16S rDNA sequence analysis. J Med Microbiol. 2000;49:817–822.PubMed Monstein HJ, Tiveljung A, Kraft CH, et al. Profiling of bacterial flora in gastric biopsies from patients with Helicobacter pylori-associated gastritis and histologically normal control individuals by temperature gradient gel electrophoresis and 16S rDNA sequence analysis. J Med Microbiol. 2000;49:817–822.PubMed
66.
go back to reference Bik EM, Eckburg PB, Gill SR, et al. Molecular analysis of the bacterial microbiota in the human stomach. Proc Natl Acad Sci U S A. 2006;103:732–737.PubMedPubMedCentral Bik EM, Eckburg PB, Gill SR, et al. Molecular analysis of the bacterial microbiota in the human stomach. Proc Natl Acad Sci U S A. 2006;103:732–737.PubMedPubMedCentral
67.
go back to reference Dicksved J, Lindberg M, Rosenquist M, et al. Molecular characterization of the stomach microbiota in patients with gastric cancer and in controls. J Med Microbiol. 2009;58:509–516.PubMed Dicksved J, Lindberg M, Rosenquist M, et al. Molecular characterization of the stomach microbiota in patients with gastric cancer and in controls. J Med Microbiol. 2009;58:509–516.PubMed
68.
go back to reference Delong EF. Preface. Microbial metagenomics, metatranscriptomics, and metaproteomics. Methods Enzymol. 2013;531:21. Delong EF. Preface. Microbial metagenomics, metatranscriptomics, and metaproteomics. Methods Enzymol. 2013;531:21.
69.
go back to reference Zhu Z, Ren J, Michail S, et al. Correction to: MicroPro: using metagenomic unmapped reads to provide insights into human microbiota and disease associations. Genome Biol. 2019;20:214.PubMedPubMedCentral Zhu Z, Ren J, Michail S, et al. Correction to: MicroPro: using metagenomic unmapped reads to provide insights into human microbiota and disease associations. Genome Biol. 2019;20:214.PubMedPubMedCentral
70.
go back to reference Andersson AF, Lindberg M, Jakobsson H, et al. Comparative analysis of human gut microbiota by barcoded pyrosequencing. PLoS One. 2008;3:e2836.PubMedPubMedCentral Andersson AF, Lindberg M, Jakobsson H, et al. Comparative analysis of human gut microbiota by barcoded pyrosequencing. PLoS One. 2008;3:e2836.PubMedPubMedCentral
71.
go back to reference Vuik F, Dicksved J, Lam SY, et al. Composition of the mucosa-associated microbiota along the entire gastrointestinal tract of human individuals. United Eur Gastroenterol J. 2019;7:897–907. Vuik F, Dicksved J, Lam SY, et al. Composition of the mucosa-associated microbiota along the entire gastrointestinal tract of human individuals. United Eur Gastroenterol J. 2019;7:897–907.
72.
go back to reference Chen L, Xu W, Lee A, et al. The impact of Helicobacter pylori infection, eradication therapy and probiotic supplementation on gut microenvironment homeostasis: An open-label, randomized clinical trial. EBioMedicine. 2018;35:87–96.PubMedPubMedCentral Chen L, Xu W, Lee A, et al. The impact of Helicobacter pylori infection, eradication therapy and probiotic supplementation on gut microenvironment homeostasis: An open-label, randomized clinical trial. EBioMedicine. 2018;35:87–96.PubMedPubMedCentral
73.
go back to reference Maldonado-Contreras A, Goldfarb KC, Godoy-Vitorino F, et al. Structure of the human gastric bacterial community in relation to Helicobacter pylori status. ISME J. 2011;5:574–579.PubMed Maldonado-Contreras A, Goldfarb KC, Godoy-Vitorino F, et al. Structure of the human gastric bacterial community in relation to Helicobacter pylori status. ISME J. 2011;5:574–579.PubMed
74.
go back to reference Aviles-Jimenez F, Vazquez-Jimenez F, Medrano-Guzman R, et al. Stomach microbiota composition varies between patients with non-atrophic gastritis and patients with intestinal type of gastric cancer. Sci Rep. 2014;4:4202.PubMedPubMedCentral Aviles-Jimenez F, Vazquez-Jimenez F, Medrano-Guzman R, et al. Stomach microbiota composition varies between patients with non-atrophic gastritis and patients with intestinal type of gastric cancer. Sci Rep. 2014;4:4202.PubMedPubMedCentral
75.
go back to reference Liu X, Shao L, Liu X, et al. Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer. EBioMedicine. 2019;40:336–348.PubMed Liu X, Shao L, Liu X, et al. Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer. EBioMedicine. 2019;40:336–348.PubMed
76.
go back to reference Ferreira RM, Pereira-Marques J, Pinto-Ribeiro I, et al. Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota. Gut. 2018;67:226–236.PubMed Ferreira RM, Pereira-Marques J, Pinto-Ribeiro I, et al. Gastric microbial community profiling reveals a dysbiotic cancer-associated microbiota. Gut. 2018;67:226–236.PubMed
77.
go back to reference Langille MG, Zaneveld J, Caporaso JG, et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat Biotechnol. 2013;31:814–821.PubMedPubMedCentral Langille MG, Zaneveld J, Caporaso JG, et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat Biotechnol. 2013;31:814–821.PubMedPubMedCentral
78.
go back to reference Coker OO, Dai Z, Nie Y, et al. Mucosal microbiome dysbiosis in gastric carcinogenesis. Gut. 2018;67:1024–1032.PubMed Coker OO, Dai Z, Nie Y, et al. Mucosal microbiome dysbiosis in gastric carcinogenesis. Gut. 2018;67:1024–1032.PubMed
79.
go back to reference Noto JM, Peek RM Jr. The gastric microbiome, its interaction with Helicobacter pylori, and its potential role in the progression to stomach cancer. PLoS Pathog. 2017;13:e1006573.PubMedPubMedCentral Noto JM, Peek RM Jr. The gastric microbiome, its interaction with Helicobacter pylori, and its potential role in the progression to stomach cancer. PLoS Pathog. 2017;13:e1006573.PubMedPubMedCentral
80.
go back to reference Castano-Rodriguez N, Goh KL, Fock KM, et al. Dysbiosis of the microbiome in gastric carcinogenesis. Sci Rep. 2017;7:15957.PubMedPubMedCentral Castano-Rodriguez N, Goh KL, Fock KM, et al. Dysbiosis of the microbiome in gastric carcinogenesis. Sci Rep. 2017;7:15957.PubMedPubMedCentral
81.
go back to reference Mailhe M, Ricaboni D, Vitton V, et al. Repertoire of the gut microbiota from stomach to colon using culturomics and next-generation sequencing. BMC Microbiol. 2018;18:157.PubMedPubMedCentral Mailhe M, Ricaboni D, Vitton V, et al. Repertoire of the gut microbiota from stomach to colon using culturomics and next-generation sequencing. BMC Microbiol. 2018;18:157.PubMedPubMedCentral
82.
go back to reference Park CH, Lee AR, Lee YR, et al. Evaluation of gastric microbiome and metagenomic function in patients with intestinal metaplasia using 16S rRNA gene sequencing. Helicobacter. 2019;24:e12547.PubMed Park CH, Lee AR, Lee YR, et al. Evaluation of gastric microbiome and metagenomic function in patients with intestinal metaplasia using 16S rRNA gene sequencing. Helicobacter. 2019;24:e12547.PubMed
83.
go back to reference Sung J, Kim N, Kim J, et al. Comparison of gastric microbiota between gastric juice and mucosa by next generation sequencing method. J Cancer Prev. 2016;21:60–65.PubMedPubMedCentral Sung J, Kim N, Kim J, et al. Comparison of gastric microbiota between gastric juice and mucosa by next generation sequencing method. J Cancer Prev. 2016;21:60–65.PubMedPubMedCentral
84.
go back to reference Gevers D, Kugathasan S, Denson LA, et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe. 2014;15:382–392.PubMedPubMedCentral Gevers D, Kugathasan S, Denson LA, et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe. 2014;15:382–392.PubMedPubMedCentral
85.
go back to reference Carstens A, Roos A, Andreasson A, et al. Differential clustering of fecal and mucosa-associated microbiota in ‘healthy’ individuals. J Dig Dis. 2018;19:745–752.PubMed Carstens A, Roos A, Andreasson A, et al. Differential clustering of fecal and mucosa-associated microbiota in ‘healthy’ individuals. J Dig Dis. 2018;19:745–752.PubMed
86.
go back to reference Saffarian A, Mulet C, Regnault B et al. Crypt- and mucosa-associated core microbiotas in humans and their alteration in colon cancer patients. MBio 2019;10. Saffarian A, Mulet C, Regnault B et al. Crypt- and mucosa-associated core microbiotas in humans and their alteration in colon cancer patients. MBio 2019;10.
Metadata
Title
Microbiome and Gastric Cancer
Authors
Lars Engstrand
David Y. Graham
Publication date
01-03-2020
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 3/2020
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-020-06101-z

Other articles of this Issue 3/2020

Digestive Diseases and Sciences 3/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.